LEXARIA BIOSCIENCE CORP.

LEXX

CIK 0001348362 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-02-28) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$20K
↓-88.5% -$154Kvs FY2025 (Q1)
Gross Profit
$20K
↓-88.5% -$154Kvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
15/100
  • Profitability
    0ROIC -176.3% (10% = solid, 20%+ = moat)
  • Liquidity
    91Current Ratio 2.32 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.11x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -88.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -7259.5% · trend -3001.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$41K
investment in PP&E
Stock-based comp (TTM)
$743K
non-cash dilution

Balance sheet · 2026-02-28

latest filed snapshot
Total assets
$6M
everything owned
Total liabilities
$277K
everything owed
Stockholders' equity
$7M
shareholder claim

Recent performance · 68 quarters

Revenue↓-88.5% -$154K
$20K
Net Income↑+46.6% +$1M
$-1M
Free Cash Flow↓-4081500.0% -$41K
$-41K
Operating Margin↓-5678.5pts
-7259.5%

Drill down